- Home
- FTHM vs PMN Comparison
FTHM vs PMN Comparison
Compare FTHM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- PMN
- Stock Information
- Founded
- FTHM 2010
- PMN 2004
- Country
- FTHM United States
- PMN Canada
- Employees
- FTHM N/A
- PMN N/A
- Industry
- FTHM Real Estate
- PMN Pharmaceuticals and Biotechnology
- Sector
- FTHM Finance
- PMN Health Care
- Exchange
- FTHM Nasdaq
- PMN Nasdaq
- Market Cap
- FTHM 56.5M
- PMN 29.6M
- IPO Year
- FTHM 2020
- PMN N/A
- Fundamental
- Price
- FTHM $2.55
- PMN $0.95
- Analyst Decision
- FTHM Strong Buy
- PMN
- Analyst Count
- FTHM 4
- PMN 0
- Target Price
- FTHM $4.25
- PMN N/A
- AVG Volume (30 Days)
- FTHM 40.9K
- PMN 61.1K
- Earning Date
- FTHM 11-06-2024
- PMN 11-12-2024
- Dividend Yield
- FTHM N/A
- PMN N/A
- EPS Growth
- FTHM N/A
- PMN N/A
- EPS
- FTHM N/A
- PMN N/A
- Revenue
- FTHM $327,306,000.00
- PMN N/A
- Revenue This Year
- FTHM N/A
- PMN N/A
- Revenue Next Year
- FTHM $21.46
- PMN N/A
- P/E Ratio
- FTHM N/A
- PMN N/A
- Revenue Growth
- FTHM N/A
- PMN N/A
- 52 Week Low
- FTHM $1.32
- PMN $0.92
- 52 Week High
- FTHM $4.33
- PMN $3.10
- Technical
- Relative Strength Index (RSI)
- FTHM 45.80
- PMN 29.18
- Support Level
- FTHM $2.67
- PMN $1.22
- Resistance Level
- FTHM $2.90
- PMN $1.07
- Average True Range (ATR)
- FTHM 0.18
- PMN 0.09
- MACD
- FTHM -0.00
- PMN -0.01
- Stochastic Oscillator
- FTHM 43.55
- PMN 7.14
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.